<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04504851</url>
  </required_header>
  <id_info>
    <org_study_id>ROSETTA</org_study_id>
    <nct_id>NCT04504851</nct_id>
  </id_info>
  <brief_title>Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct</brief_title>
  <acronym>ROSETTA</acronym>
  <official_title>Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial aims to determine whether the addition of rosuvastatin to standard TB therapy in&#xD;
      pulmonary tuberculosis results in accelerated of sputum culture conversion. The trial will&#xD;
      also investigate potential new biomarkers of sterilising activity and immune-modulatory&#xD;
      activity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rosuvastatin is an HMG Co-A reductase inhibitor which may be of value as possible adjunctive&#xD;
      agents to standard TB therapy. Cell culture assays and animal models demonstrate that statins&#xD;
      are bactericidal against Mtb with effects that are additive to that of anti-tuberculous&#xD;
      therapy.&#xD;
&#xD;
      This is a Phase IIb randomised, controlled, open-label, early bactericidal activity trial. We&#xD;
      will recruit patients between the ages of 18 and 75 with newly-diagnosed smear or Xpert&#xD;
      positive pulmonary TB, who have had no more than 7 days of TB therapy.&#xD;
&#xD;
      Patients will be randomised to take either standard TB therapy or standard TB therapy plus&#xD;
      rosuvastatin for the first 8 weeks of their therapy. After the first 8 weeks, patients will&#xD;
      continue standard combination TB therapy and remain in trial follow-up until week 24. The&#xD;
      trial will collect sputum for culture on a weekly basis for the first 8 weeks of the trial,&#xD;
      and less frequently leading up to week 24.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 12, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to culture conversion in Liquid Media</measure>
    <time_frame>within 8 weeks after randomisation</time_frame>
    <description>Time to culture conversion is defined is time from randomisation to the first of two consecutive negative sputum cultures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to culture conversion in Solid media</measure>
    <time_frame>within 8 weeks after randomisation</time_frame>
    <description>Time to culture conversion is defined is time from randomisation to the first of two consecutive negative sputum cultures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to culture conversion in Liquid media</measure>
    <time_frame>within 12 weeks after randomisation</time_frame>
    <description>Time to culture conversion is defined is time from randomisation to the first of two consecutive negative sputum cultures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum culture negative in Liquid media</measure>
    <time_frame>at 8 weeks from randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum culture negative in Solid media</measure>
    <time_frame>at 8 weeks from randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in time to positivity (TTP)</measure>
    <time_frame>from baseline to week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in proportion of lung affected on CXR</measure>
    <time_frame>from baseline to week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the aggregate cavity size on CXR</measure>
    <time_frame>from baseline to week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in score on St George's Respiratory Questionnaire (SGRQ)</measure>
    <time_frame>from baseline to week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FEV1/FVC</measure>
    <time_frame>from baseline to week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One or more Grade 3 or Grade 4 adverse events</measure>
    <time_frame>by week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One of more Serious Adverse Events (SAEs)</measure>
    <time_frame>by week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Pulmonary Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Arm A (Standard of Care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard combination treatment for pulmonary TB of 8 weeks rifampicin, isoniazid, pyrazinamide, ethambutol, then 16 weeks rifampicin, isoniazid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Standard of Care plus Rosuvastatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard combination treatment for pulmonary TB of 8 weeks rifampicin, isoniazid, pyrazinamide, ethambutol PLUS rosuvastatin, then 16 weeks rifampicin, isoniazid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 10mg</intervention_name>
    <description>10mg of Rosuvastatin in the Intensive Phase of Therapy (8 weeks)</description>
    <arm_group_label>Arm B (Standard of Care plus Rosuvastatin)</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin</intervention_name>
    <description>Rifampicin 10mg/kg</description>
    <arm_group_label>Arm A (Standard of Care)</arm_group_label>
    <arm_group_label>Arm B (Standard of Care plus Rosuvastatin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid</intervention_name>
    <description>Isoniazid 5mg/kg</description>
    <arm_group_label>Arm A (Standard of Care)</arm_group_label>
    <arm_group_label>Arm B (Standard of Care plus Rosuvastatin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrazinamide</intervention_name>
    <description>Pyrazinamide 25mg/kg</description>
    <arm_group_label>Arm A (Standard of Care)</arm_group_label>
    <arm_group_label>Arm B (Standard of Care plus Rosuvastatin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethambutol</intervention_name>
    <description>Ethambutol 15mg/kg</description>
    <arm_group_label>Arm A (Standard of Care)</arm_group_label>
    <arm_group_label>Arm B (Standard of Care plus Rosuvastatin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18 - 75 years of age&#xD;
&#xD;
          2. Abnormalities on CXR compatible with pulmonary TB&#xD;
&#xD;
          3. At least one sputum specimen, produced at or prior to screening during the current&#xD;
             illness episode, that is:&#xD;
&#xD;
             (i) positive for acid-fast bacilli on smear microscopy (with at least 1+ on the&#xD;
             IUATLD/WHO scale) and/or (ii) positive on testing by Xpert MTB/RIF or Xpert Ultra&#xD;
             (with semi-quantitative cycle threshold (CT) result of 'medium' or 'high')&#xD;
&#xD;
          4. Able to produce at least 5ml of sputum per day at the time of screening&#xD;
&#xD;
          5. Current or planned treatment with a regimen containing rifampicin, isoniazid and&#xD;
             pyrazinamide (with or without ethambutol) only&#xD;
&#xD;
          6. Resident at a fixed address within feasible travelling distance to the site and likely&#xD;
             to remain a local resident for the duration of trial follow-up&#xD;
&#xD;
          7. Willing to have directly observed therapy (DOT)&#xD;
&#xD;
          8. Willing to comply with the study visits and procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. More than 7 days of standard TB treatment by the time of the baseline visit&#xD;
&#xD;
          2. Known rifampicin resistance or isoniazid resistance at the time of randomization&#xD;
             (results by conventional DST or molecular tests are not required to be available prior&#xD;
             to randomization)&#xD;
&#xD;
          3. Previous treatment for active TB disease, unless rifampicin susceptibility has been&#xD;
             demonstrated on a molecular test performed during this episode.&#xD;
&#xD;
          4. Extrapulmonary TB that, in the opinion of the treating clinician, is likely to require&#xD;
             concurrent use of steroids, or require surgical management.&#xD;
&#xD;
          5. Known hypersensitivity to rosuvastatin&#xD;
&#xD;
          6. History of myopathy or family history of hereditary muscular disorders&#xD;
&#xD;
          7. Acute liver failure or decompensated chronic liver disease&#xD;
&#xD;
          8. Current alcohol abuse&#xD;
&#xD;
          9. Known hypothyroidism&#xD;
&#xD;
         10. Any of the following laboratory parameters at screening:&#xD;
&#xD;
               1. ALT &gt;3 times upper limit of normal (ULN)&#xD;
&#xD;
               2. Estimated glomerular filtration rate (eGFR) &lt; 60ml/min/1.73m2 (calculated using&#xD;
                  the CKD-EPI equation) (81)&#xD;
&#xD;
               3. Creatine Kinase &gt;5 times ULN&#xD;
&#xD;
               4. Potassium &lt;2.5 mmol/L&#xD;
&#xD;
         11. Active malignancy on chemotherapy or radiotherapy&#xD;
&#xD;
         12. Current use of immunosuppressive medication (≤ 5mg/ day of prednisolone or equivalent&#xD;
             is acceptable).&#xD;
&#xD;
         13. HIV infection (unless patient has been stable on continuous antiretroviral therapy for&#xD;
             at least 6 months, with CD4 count &gt;/= 250 cells/mm3 and viral load &lt;/= 200 copies/ml,&#xD;
             on a test performed at screening or during the last 12 months prior to screening, in&#xD;
             which case they may be enrolled)&#xD;
&#xD;
         14. Use of any statin drug at screening or during the 3 months prior to screening&#xD;
&#xD;
         15. History of Atherosclerotic Cardiovascular Disease (ASCVD; defined as myocardial&#xD;
             infarction, stable or unstable angina, coronary artery disease or coronary or other&#xD;
             arterial revascularization, stroke, transient ischemic attack, or peripheral artery&#xD;
             disease including aortic aneurysm, all of atherosclerotic origin)&#xD;
&#xD;
         16. Known Familial Hypercholesterolaemia&#xD;
&#xD;
         17. Other reasons, in the opinion of the investigator (and taking into consideration&#xD;
             current local and international guidelines for primary prevention of cardiovascular&#xD;
             disease), why the patient should commence statin treatment during the 6-month period&#xD;
             following randomization&#xD;
&#xD;
         18. Current use of drugs contraindicated for use with rosuvastatin or standard TB drugs&#xD;
             including fusidic acid, gemfibrozil, feno-fibrate, nicotinic acid (&gt;1 gram/day),&#xD;
             cyclosporine, directly acting antivirals for chronic Hepatitis C, protease inhibitors&#xD;
             for HIV and praziquantel.&#xD;
&#xD;
         19. Women who are pregnant or breastfeeding&#xD;
&#xD;
         20. Women of childbearing potential unwilling or unable to use appropriate effective&#xD;
             contraception for the first 12 weeks of the trial.&#xD;
&#xD;
         21. Any serious condition suggestive of myopathy or predisposing to the development of&#xD;
             renal failure secondary to rhabdomyolysis (such as extensive surgery, significant&#xD;
             trauma, uncontrolled seizures)&#xD;
&#xD;
         22. Any other severe underlying condition that would, in the opinion of the investigator,&#xD;
             compromise the patient's safety or outcome in the trial.&#xD;
&#xD;
         23. Participation in other clinical intervention trial or research protocol (participation&#xD;
             in other studies that do not involve an intervention may be allowed, but this must be&#xD;
             discussed and approved by the Chief Investigator).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Paton</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Hospital, Singapore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gail Cross</last_name>
    <phone>+65 83280377</phone>
    <email>mdcgbc@nus.edu.sg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicholas Paton</last_name>
    <phone>+65 6601 5371</phone>
    <email>mdcnijp@nus.edu.sg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tropical Disease Foundation</name>
      <address>
        <city>Makati City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>De La Salle Health Sciences Institute</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lung Center Philippines</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital, Singapore</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joint Clinical Research Centre</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vietnam Military Medical University</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
    <country>Singapore</country>
    <country>Uganda</country>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 5, 2020</study_first_submitted>
  <study_first_submitted_qc>August 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2020</study_first_posted>
  <last_update_submitted>August 5, 2020</last_update_submitted>
  <last_update_submitted_qc>August 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Statin</keyword>
  <keyword>Rosuvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Pyrazinamide</mesh_term>
    <mesh_term>Ethambutol</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

